BTIG notes Arvinas (ARVN) is down about 7% today, which the firm thinks is due to investors seeing a negative read-through to Arvinas from data from Eli Lilly’s (LLY) Phase 3 EMBER-3 trial in recurrent ER+/HER2- breast cancer given the “compelling” 9.4 months progression free survival seen with the imlunestrant plus abemaciclib combo. However, the firm says its assumption of a 3.5 to 4.5 months fulvestrant arm performance for VERITAC-2 remains intact and it continues to see vepdegestrant as a better degrader than imlunestrant. BTIG has a Buy rating and $69 price target on Arvinas shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Arvinas and Pfizer Report Promising Cancer Study Results
- Arvinas, Pfizer announce initial Phase 1b data from TACTIVE-U sub-study
- Arvinas initiated with a Buy at BTIG
- Truist biopharma analyst to hold an analyst/industry conference call